ID: h-00073ccb
Hypothesis
DNA Methylation Clock Drift at Glial Promoters
DNA Methylation Clock Drift at Glial Promoters.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
⚠ Thin Description Senate Quality Gates →
🧪 Overview
DNA Methylation Clock Drift at Glial Promoters
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["DNA Methylation Clock<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["Neurodegeneration<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends.
Supports
Homologous recombination and the repair of DNA double-strand breaks.
Supports
Regulation of Human DNA Primase-Polymerase PrimPol.
Contradicts
A systematic review of epigenetic clocks in neurodegenerative diseases highlights heterogeneous evidence and limits causal interpretation of clock acceleration.
Contradicts
Brain epigenetic-clock associations with pathology and aging phenotypes are not equivalent to promoter-specific glial causality.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — DNA
No curated PDB or AlphaFold mapping for DNA yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for DNA Methylation Clock.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0191
Events (7d)
0
Price History
▲5.6%💾 Resource Usage
LLM Tokens
36,950
$0.1109
Total Cost
$0.1109
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF glial promoter methylation drift contributes to neurodegeneration, THEN CRISPR-Cas9 mediated repression of DNMT3A at candidate drifted glial promoters (via dCas9-DNMT3A targeting GFAP, ALDH1L1, OLI | ≥40% reduction in AT8+ cells and ≥25% improvement in Morris water maze performance | — no observation — | pending | 0.35 |
| IF DNA methylation clock drift selectively accelerates at glial promoters in neurodegeneration, THEN isolated astrocytes and oligodendrocytes from post-mortem prefrontal cortex of Alzheimer's disease | Glial epigenetic age acceleration >2.5 years in neurodegeneration cohort vs. control | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF DNA methylation clock drift selectively accelerates at glial promoters in neurodegeneration, THEN isolated astrocytes and oligodendrocytes from post-mortem prefrontal cortex of Alzheimer's disease patients (Braak stage IV-VI) will show a statistically significant increase in epigenetic age accele
Predicted outcome: Glial epigenetic age acceleration >2.5 years in neurodegeneration cohort vs. control
Falsification: No significant difference in epigenetic age between neurodegeneration and control glial cells, OR glial epigenetic age deceleration in disease states (p > 0.05 by Mann-Whitney U test with Bonferroni c
pendingconf 35%
IF glial promoter methylation drift contributes to neurodegeneration, THEN CRISPR-Cas9 mediated repression of DNMT3A at candidate drifted glial promoters (via dCas9-DNMT3A targeting GFAP, ALDH1L1, OLIG2 promoters) in human iPSC-derived astrocytes transplanted into humanized mouse brain will signific
Predicted outcome: ≥40% reduction in AT8+ cells and ≥25% improvement in Morris water maze performance
Falsification: No significant reduction in tau pathology markers OR no behavioral improvement OR increased gliosis in intervention group (two-tailed t-test, α=0.05; sample size n≥12 per group, power=0.80)
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.